Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Type of study
Language
Publication year range
1.
Pharmacol Res ; 48(1): 37-48, 2003 Jul.
Article in English | MEDLINE | ID: mdl-12770513

ABSTRACT

The effects of selective ((5,5-dimethyl-3-(3-florophenyl)-4-(4-methylsulphonyl-2(5H)-furanon); DFU) and (N-(2-cyclohexyloxy-4-nitrophenyl)-methansulphonamide; NS 398)) or non-selective (diclophenac and proquazon) inducible cyclooxygenase (COX-2) inhibitors on the survival, nitrite (stable product of nitric oxide (NO) as an index for inducible NO synthase (iNOS) activity) and 6-keto-prostaglandin F(1alpha) (6-keto-PGF(1alpha), stable product of prostacyclin as an index for COX-2 activity) production in serum, lungs, brain and/or kidney were investigated in endotoxin-induced sepsis model in mice. Endotoxin (10 mg x kg(-1), i.p.)-induced mortality was prevented by DFU, NS 398 and proquazon (0.1, 10 and 1 mg x kg(-1), respectively) and enhanced 2.6-fold with 0.1mg x kg(-1) diclophenac. Endotoxin-induced increase in the serum levels of nitrite was only inhibited by 10 mg x kg(-1) diclophenac. Endotoxin caused a significant decrease only in the brain levels of nitrite without affecting 6-keto-PGF(1alpha) levels in all tissues. The decreased levels of nitrite induced by endotoxin is further reduced by 0.1mg x kg(-1) DFU and 1 and 10mg x kg(-1) diclophenac while 10 mg x kg(-1) DFU and 1mg x kg(-1) proquazon increased it. On the other hand, 1mg x kg(-1) diclophenac and proquazon, and 10 mg x kg(-1) NS 398 increased the endotoxin-induced lung levels of 6-keto-PGF(1alpha). The results suggest that the COX inhibitors may have different effects on the survival and NO production depending on tissue and dose.


Subject(s)
6-Ketoprostaglandin F1 alpha/metabolism , Cyclooxygenase Inhibitors/pharmacology , Nitric Oxide/biosynthesis , Sepsis/metabolism , Analysis of Variance , Animals , Cyclooxygenase Inhibitors/therapeutic use , Diclofenac/pharmacology , Diclofenac/therapeutic use , Disease Models, Animal , Female , Furans/pharmacology , Furans/therapeutic use , Lipopolysaccharides , Male , Mice , Nitric Oxide Synthase/drug effects , Nitric Oxide Synthase/metabolism , Nitric Oxide Synthase Type II , Nitrites/blood , Nitrites/metabolism , Nitrobenzenes/pharmacology , Nitrobenzenes/therapeutic use , Prostaglandin-Endoperoxide Synthases/metabolism , Quinazolines/pharmacology , Quinazolines/therapeutic use , Sepsis/drug therapy , Sepsis/etiology , Sepsis/mortality , Sulfonamides/pharmacology , Sulfonamides/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...